Background: 2-(4'- [11C]Methylaminophenyl)-6-hydroxybenzothiazole ([11C]-PiB), purportedly a specific imaging agent for cerebral amyloid-β plaques, is a specific, high affinity substrate for estrogen sulfotransferase (SULT1E1), an enzyme that regulates estrogen homeostasis.

Objective: In this work, we use positron emission tomography (PET) imaging with [11C]-PiB to assess the functional activity of SULT1E1 in the brain of moyamoya disease patients.

Methods: Ten moyamoya subjects and five control patients were evaluated with [11C]-PiB PET and structural MRI scans. Additionally, a patient with relapsing-remitting multiple sclerosis (RRMS) received [11C]-PiB PET scans before and after steroidal and immunomodulatory therapy. Parametric PET images were established to assess SULT1E1 distribution in the inflamed brain tissue.

Results: Increased [11C]-PiB SRTM DVR in the thalamus, pons, corona radiata, and internal capsule of moyamoya cohort subjects was observed in comparison with controls (p ≤ 0.01). This was observed in patients without treatment, with collateralization, and also after radiation. The post-treatment [11C]-PiB PET scan in one RRMS patient also revealed substantially reduced subcortical brain inflammation. In validation studies, [11C]-PiB autoradiography signal in the peri-infarct area of the rat middle cerebral arterial occlusion stroke model was shown to correlate with SULT1E1 immunohistochemistry.

Conclusion: Strong [11C]-PiB PET signal associated with intracranial inflammation in the moyamoya syndrome cohort and a single RRMS patient appears consistent with functional imaging of SULT1E1 activity in the human brain. This preliminary work offers substantial and direct evidence that significant [11C]-PiB PET focal signals can be obtained from the living human brain with intracranial inflammation, signals not attributable to amyloid-β plaques.

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-190559DOI Listing

Publication Analysis

Top Keywords

[11c]-pib pet
20
human brain
12
[11c]-pib
10
living human
8
amyloid-β plaques
8
rrms patient
8
intracranial inflammation
8
pet
7
brain
6
sult1e1
5

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea, Republic of (South).

Background: Alzheimer's disease (AD) pathology occurs in the brain before manifestation of significant cognitive decline. Growing evidence suggests that brain networks such as default mode network (DMN) or salience network, identified through resting-state functional magnetic resonance imaging (MRI), are affected by AD pathology. In this study, we investigated the relationship between network segregation and the key in vivo AD pathologies including beta-amyloid (Aβ) and tau deposition in old adults with no cognitive impairment.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, St Louis, MO, USA.

Background: Differences in amyloid PET radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid uptake measurements, which may adversely affect the statistical power of clinical trials that utilize multiple tracers to track brain amyloid deposition. To address this, Centiloid was developed for standardizing global amyloid SUVRs across tracers to a common scale. Alternatively, ComBat is a technique for harmonizing batch effects while preserving variations from biologically-relevant covariates.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Faculty of Medicine, Oita University, Oita, Japan.

Background: Abnormal amyloid-β (Aβ) deposition in the brain has been defined as the earliest pathological change of Alzheimer disease (AD). Immunoprecipitation coupled with MALDI-TOF MS (IP-MS) has previously revealed that APP669-711/Aβ1-42 ratio, Aβ1-40/Aβ1-42 ratio, and a combination of these two biomarkers (a composite biomarker) in human plasma correlates highly with SUVR obtained from amyloid PET. In this work, we investigate the usefulness of plasma Aβ biomarkers at baseline in predicting the conversion to AD dementia.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

CSIRO Health and Biosecurity, Australian E-Health Research Centre, Parkville, VIC, Australia.

Background: PET quantification using the Standardised Uptake Value Ratio (SUVR) relies on the availability of a robust reference region. Intrinsic noise, spill in, and specific binding in the reference region can impact the reliability of the resulting SUVR. We evaluate a novel deep learning method trained on longitudinal data that penalises unexpected temporal changes and learns a SUVR correction factor that compensates for any noise or bias in the reference region, resulting in an improved quantification.

View Article and Find Full Text PDF

Background: Brain-predicted age estimates are used to quantify an individual's brain age compared to a normative trajectory. We have recently shown that brain age from structural MRI is elevated in autosomal dominant Alzheimer disease (ADAD), a unique sample that allows the study of AD progression independently of age-related confounds. Resting-state functional connectivity (FC) may capture a biphasic response to sporadic AD, and thus may complement structural measures of brain aging in ADAD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!